AUTHOR=Busca Alessandro , Salmanton-García Jon , Marchesi Francesco , Farina Francesca , Seval Guldane Cengiz , Van Doesum Jaap , De Jonge Nick , Bahr Nathan C. , Maertens Johan , Meletiadis Joseph , Fracchiolla Nicola S. , Weinbergerová Barbora , Verga Luisa , Ráčil Zdeněk , Jiménez Moraima , Glenthøj Andreas , Blennow Ola , Tanase Alina Daniela , Schönlein Martin , Prezioso Lucia , Khanna Nina , Duarte Rafael F. , Žák Pavel , Nucci Marcio , Machado Marina , Kulasekararaj Austin , Espigado Ildefonso , De Kort Elizabeth , Ribera-Santa Susana José-María , Marchetti Monia , Magliano Gabriele , Falces-Romero Iker , Ilhan Osman , Ammatuna Emanuele , Zompi Sofia , Tsirigotis Panagiotis , Antoniadou Anastasia , Zambrotta Giovanni Paolo Maria , Nordlander Anna , Karlsson Linda Katharina , Hanakova Michaela , Dragonetti Giulia , Cabirta Alba , Berg Venemyr Caroline , Gräfe Stefanie , Van Praet Jens , Tragiannidis Athanasios , Petzer Verena , López-García Alberto , Itri Federico , Groh Ana , Gavriilaki Eleni , Dargenio Michelina , Rahimli Laman , Cornely Oliver A. , Pagano Livio , EPICOVIDEHA Consortium , Prattes Juergen , Mikulska Malgorzata , Méndez Gustavo-Adolfo , Lahmer Tobias , Jindra Pavel , Guidetti Anna , Fazzi Rita , Principe Maria Ilaria Del , Ramón Cristina De , Calbacho Maria , Stojanoski Zlate , Soto Andrés , Serris Alexandra , Ormazabal-Vélez Irati , Omrani Ali S. , Navrátil Milan , Martín-Pérez Sonia , Almeida Joyce Marques De , Lamure Sylvain , Kolditz Martin , Jaksic Ozren , Hoenigl Martin , Garcia-Vidal Carolina , Fernández Noemí , El-Ashwah Shaimaa , Čolović Natasha , Čerňan Martin , Buquicchio Caterina , Bonuomo Valentina , Batinić Josip , Al-Khabori Murtadha , Adžić-Vukičević Tatjana , Martín-González Juan-Alberto , Sacchi Maria Vittoria , Jiménez-Lorenzo María-Josefa , Wolf Dominik , Vehreschild Maria , Cordoba Raul , García-Sanz Ramón , Valković Toni , Mladenović Miloš , García-Poutón Nicole , Emarah Ziad , Dávila-Valls Julio TITLE=Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry JOURNAL=Frontiers in Immunology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1125030 DOI=10.3389/fimmu.2023.1125030 ISSN=1664-3224 ABSTRACT=Background

The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT.

Methods

This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022.

Results

The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53).

Conclusions

Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.